You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
华领医药(02552.HK)发表糖尿病用药之研究进展
阿思达克 11-26 08:31
华领医药(02552.HK)公布,在中华医学会糖尿病学分会第二十四次全国学术会议(CDS 2020)上,公司将通过口头报告和专题讨论会对DAWN研究进行报告。24周研究资料显示,针对二甲双胍足量治疗(1500mg/天)失效的2型糖尿病患者,多?格列艾汀治疗组HbA1c较基线降低1.02%,比安慰剂对照组多下降0.66%(安慰剂组为0.36%),p值<0.0001,药效显着,明显优於二甲双胍单药治疗。

此外,多?格列艾汀与SGLT-2抑制剂、与DPP-4抑制剂等主要治疗药物的联合用药临床研究结果均表明,联合用药具有明显增效作用,能够显着提高血糖控制能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account